RATIONALE: Inflammation and autonomic dysfunction contribute to the pathophysiology of hypertension. Cholinergic stimulation suppresses innate immune responses. Angiotensin II (Ang II) induces hypertension and is associated with proinflammatory immune responses. OBJECTIVE: Our goal was to define the innate immune response in a model of genetic hypertension and the influences of cholinergic stimulation and Ang II. METHODS AND RESULTS: Studies were conducted on 4- to 5-week-old prehypertensive spontaneously hypertensive rats (SHRs) and age-matched normotensive control, Wistar Kyoto (WKY) rats. Isolated splenocytes were preexposed to nicotine or Ang II before Toll-like receptor (TLR) activation. Culture supernatants were tested for cytokines (tumor necrosis factor-α, interleukin [IL]-10, and IL-6). TLR-mediated cytokine responses were most pronounced with TLR7/8 and TLR9 activation and similar between WKY rats and SHRs. Nicotine and Ang II enhanced this TLR-mediated IL-6 response in prehypertensive SHR splenocytes. In contrast, nicotine suppressed the TLR-mediated IL-6 response in WKY rats, whereas Ang II had no effect. In vivo, nicotine enhanced plasma levels of TLR7/8-mediated IL-6 and IL-1β responses in prehypertensive SHRs but suppressed these responses in WKY rats. Flow cytometry revealed an increase in a CD161+ innate immune cell population, which was enhanced by nicotine in the prehypertensive SHR spleen but not in WKY. CONCLUSIONS: There is a pronounced anti-inflammatory nicotinic/cholinergic modulation of the innate immune system in WKY rats, which is reversed in prehypertensive SHRs. The results support the novel concept that neurohormonal regulation of the innate immune system plays a role in the pathogenesis of genetic hypertension and provide putative molecular targets for treatment of hypertension.
RATIONALE: Inflammation and autonomic dysfunction contribute to the pathophysiology of hypertension. Cholinergic stimulation suppresses innate immune responses. Angiotensin II (Ang II) induces hypertension and is associated with proinflammatory immune responses. OBJECTIVE: Our goal was to define the innate immune response in a model of genetic hypertension and the influences of cholinergic stimulation and Ang II. METHODS AND RESULTS: Studies were conducted on 4- to 5-week-old prehypertensive spontaneously hypertensive rats (SHRs) and age-matched normotensive control, Wistar Kyoto (WKY) rats. Isolated splenocytes were preexposed to nicotine or Ang II before Toll-like receptor (TLR) activation. Culture supernatants were tested for cytokines (tumornecrosis factor-α, interleukin [IL]-10, and IL-6). TLR-mediated cytokine responses were most pronounced with TLR7/8 and TLR9 activation and similar between WKY rats and SHRs. Nicotine and Ang II enhanced this TLR-mediated IL-6 response in prehypertensive SHR splenocytes. In contrast, nicotine suppressed the TLR-mediated IL-6 response in WKY rats, whereas Ang II had no effect. In vivo, nicotine enhanced plasma levels of TLR7/8-mediated IL-6 and IL-1β responses in prehypertensive SHRs but suppressed these responses in WKY rats. Flow cytometry revealed an increase in a CD161+ innate immune cell population, which was enhanced by nicotine in the prehypertensive SHR spleen but not in WKY. CONCLUSIONS: There is a pronounced anti-inflammatory nicotinic/cholinergic modulation of the innate immune system in WKY rats, which is reversed in prehypertensive SHRs. The results support the novel concept that neurohormonal regulation of the innate immune system plays a role in the pathogenesis of genetic hypertension and provide putative molecular targets for treatment of hypertension.
Authors: Laurel A Grisanti; Andrew P Woster; Julie Dahlman; Edward R Sauter; Colin K Combs; James E Porter Journal: J Pharmacol Exp Ther Date: 2011-05-13 Impact factor: 4.030
Authors: A Graham; J A Court; C M Martin-Ruiz; E Jaros; R Perry; S G Volsen; S Bose; N Evans; P Ince; A Kuryatov; J Lindstrom; C Gotti; E K Perry Journal: Neuroscience Date: 2002 Impact factor: 3.590
Authors: Jasenka Zubcevic; Monica M Santisteban; Teresa Pitts; David M Baekey; Pablo D Perez; Donald C Bolser; Marcelo Febo; Mohan K Raizada Journal: Hypertension Date: 2014-03-31 Impact factor: 10.190
Authors: Ulrich Wenzel; Jan Eric Turner; Christian Krebs; Christian Kurts; David G Harrison; Heimo Ehmke Journal: J Am Soc Nephrol Date: 2015-08-28 Impact factor: 10.121
Authors: Curt D Sigmund; Robert M Carey; Lawrence J Appel; Donna K Arnett; Hayden B Bosworth; William C Cushman; Zorina S Galis; Melissa Green Parker; John E Hall; David G Harrison; Alicia A McDonough; Holly L Nicastro; Suzanne Oparil; John W Osborn; Mohan K Raizada; Jacqueline D Wright; Young S Oh Journal: Hypertension Date: 2020-02-17 Impact factor: 10.190
Authors: Sailesh C Harwani; Jason Ratcliff; Fayyaz S Sutterwala; Zuhair K Ballas; David K Meyerholz; Mark W Chapleau; Francois M Abboud Journal: Circ Res Date: 2016-09-22 Impact factor: 17.367
Authors: Annette D de Kloet; Eric G Krause; Peng D Shi; Jasenka Zubcevic; Mohan K Raizada; Colin Sumners Journal: Pharmacol Ther Date: 2013-02-28 Impact factor: 12.310
Authors: Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Babak Baban; Takayuki Matsumoto; R Clinton Webb Journal: Am J Hypertens Date: 2016-09-13 Impact factor: 2.689